BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Ikeda Y, Nagase N, Tsuji A, Kitagishi Y, Matsuda S. Neuroprotection by dipeptidyl-peptidase-4 inhibitors and glucagon-like peptide-1 analogs via the modulation of AKT-signaling pathway in Alzheimer’s disease. World J Biol Chem 2021; 12(6): 104-113 [PMID: 34904048 DOI: 10.4331/wjbc.v12.i6.104]
URL: https://www.wjgnet.com/1948-9358/full/v12/i6/104.htm
Number Citing Articles
1
Dipeptidyl peptidase 4(DPP4) inhibitors stride up the management of Parkinson's diseaseEuropean Journal of Pharmacology 2023; 939: 175426 doi: 10.1016/j.ejphar.2022.175426
2
Moeka Nakashima, Naoko Suga, Sayuri Yoshikawa, Satoru Matsuda. Caveolae with GLP-1 and NMDA Receptors as Crossfire Points for the Innovative Treatment of Cognitive Dysfunction Associated with Neurodegenerative DiseasesMolecules 2024; 29(16): 3922 doi: 10.3390/molecules29163922
3
Toshiyuki Murai, Satoru Matsuda. The Chemopreventive Effects of Chlorogenic Acids, Phenolic Compounds in Coffee, against Inflammation, Cancer, and Neurological DiseasesMolecules 2023; 28(5): 2381 doi: 10.3390/molecules28052381
4
Bárbara Teruel-Peña, José Luís Gómez-Urquiza, Nora Suleiman-Martos, Isabel Prieto, Francisco José García-Cózar, Manuel Ramírez-Sánchez, Carmen Fernández-Martos, Germán Domínguez-Vías. Systematic Review and Meta-Analyses of Aminopeptidases as Prognostic Biomarkers in Amyotrophic Lateral SclerosisInternational Journal of Molecular Sciences 2023; 24(8): 7169 doi: 10.3390/ijms24087169
5
Maanvi Dhureja, Rahul Deshmukh. Impact of alogliptin on lipopolysaccharide-induced experimental Parkinson's disease: Unrevealing neurochemical and histopathological alterations in rodents.European Journal of Pharmacology 2024; 975: 176635 doi: 10.1016/j.ejphar.2024.176635
6
Agnieszka Skibska, Renata Perlikowska. Natural Plant Materials as a Source of Neuroprotective PeptidesCurrent Medicinal Chemistry 2024; 31(31): 5027 doi: 10.2174/0929867331666230703145043
7
Sayuri Yoshikawa, Kurumi Taniguchi, Haruka Sawamura, Yuka Ikeda, Ai Tsuji, Satoru Matsuda. A New Concept of Associations between Gut Microbiota, Immunity and Central Nervous System for the Innovative Treatment of Neurodegenerative DisordersMetabolites 2022; 12(11): 1052 doi: 10.3390/metabo12111052
8
Oytun Erbas, İlknur Altuntaş, Pemra Nesil, Hadi Sasani, Mehtap Odabaşı. Rare Neurodegenerative Disorders - New Insights [Working Title]2023;  doi: 10.5772/intechopen.109967
9
Moeka Nakashima. Caveolae with serotonin and NMDA receptors as promising targets for the treatment of Alzheimer’s diseaseInternational Journal of Physiology, Pathophysiology and Pharmacology 2024; 16(5): 96 doi: 10.62347/MTWV3745
10
Jie Meng, Rui Yan, Chen Zhang, Xueyan Bai, Xingsheng Yang, Yu Yang, Tao Feng, Xin Liu. Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitusLipids in Health and Disease 2023; 22(1) doi: 10.1186/s12944-023-01985-y
11
Jean-baptiste Bonnet, Axelle Trupheme Durieux, Sarah Tournayre, Lucile Marty, Ariane Sultan, Antoine Avignon. Semaglutide as a potential treatment for obesity in Smith-Kingsmore syndrome (SKS) patients: A mosaic mutation case reportObesity Research & Clinical Practice 2024; 18(2): 159 doi: 10.1016/j.orcp.2024.03.009
12
Hans-Gert Bernstein, Gerburg Keilhoff, Henrik Dobrowolny, Johann Steiner. The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS – a critical overviewReviews in the Neurosciences 2023; 34(1): 1 doi: 10.1515/revneuro-2022-0026
13
Nassima Oumata, Kui Lu, Yuou Teng, Christian Cavé, Yu Peng, Hervé Galons, Bernard P. Roques. Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic moleculesEuropean Journal of Medicinal Chemistry 2022; 240: 114578 doi: 10.1016/j.ejmech.2022.114578
14
Mohammed Alrouji, Hayder M. Al-Kuraishy, Ali I. Al-Gareeb, Athanasios Alexiou, Marios Papadakis, Hebatallah M. Saad, Gaber El-Saber Batiha. The potential role of human islet amyloid polypeptide in type 2 diabetes mellitus and Alzheimer’s diseasesDiabetology & Metabolic Syndrome 2023; 15(1) doi: 10.1186/s13098-023-01082-1